Skip to main content
Top
Published in: BMC Health Services Research 1/2015

Open Access 01-06-2015 | Research article

Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study

Authors: Indara C. Saccilotto, Rosane Isabel Bittencourt, Camila C. Fischer, Amanda Quevedo, Vania N. Hirakata, Paulo D. Picon

Published in: BMC Health Services Research | Issue 1/2015

Login to get access

Abstract

Background

Within the Brazilian Unified Health System (SUS), Referral Centers (RCs) are care facilities that provide specialized services. The objective of this study was to evaluate the efficacy of care provided to patients with multiple myeloma (MM) at a specialized RC (Hospital de Clínicas de Porto Alegre Referral Center for Multiple Myeloma, CRMM-HCPA) and to compare quality of life between patients with MM treated at CRMM-HCPA and those treated at non-RC facilities.

Methods

A 6-month cohort study was conducted in patients with MM receiving thalidomide from the Rio Grande do Sul State Health Department and treated at CRMM-HCPA and patients receiving treatment at other, non-RC care facilities. Thirty-two patients were included in the study, 19 from CRMM-HCPA and 13 from other institutions. To analyze the efficacy of care provided at CRMM-HCPA, the main outcome measure was the time from diagnosis to referral for autologous hematopoietic stem cell transplantation (HSCT). This outcome measure was assessed using questionnaires specifically designed for this study. Quality of life was also assessed, using the SF-36 questionnaire.

Results

Time from MM diagnosis to referral for autologous HSCT in each group was measured only in patients aged ≤ 65 years (n = 25); of these, 15 were recruited from CRMM-HCPA and 10 from other institutions. In this analysis, there was a significant difference (p = 0.036) in time elapsed between diagnosis and referral for autologous HSCT, which was significantly shorter for patients treated at CRMM-HCPA (median, 9 months; IQR, 8.5–14.5) than for those treated elsewhere (median, 24 months; IQR, 16–24). On quality of life analysis, there was a significant difference in the Social Functioning domain of the SF-36 questionnaire, which relates to performance of social activities (p = 0.02).

Conclusions

The Referral Center model provided seems to be a more efficient treatment strategy as compared with other health care facilities, as it enabled a reduction in time to transplantation. Patients treated at CRMM-HCPA demonstrated greater ease in performing social activities, with less interference from physical or emotional problems.
Literature
1.
go back to reference Brasil, Ministério da Saúde. Secretaria de Assistência à Saúde; Protocolos Clínicos e Diretrizes Terapêuticas: Medicamentos Excepcionais; eds. Paulo Dornelles Picon, Alberto Beltrame. Brasília: Ministério da Saúde; 2002. Brasil, Ministério da Saúde. Secretaria de Assistência à Saúde; Protocolos Clínicos e Diretrizes Terapêuticas: Medicamentos Excepcionais; eds. Paulo Dornelles Picon, Alberto Beltrame. Brasília: Ministério da Saúde; 2002.
2.
go back to reference Brasil, Ministério da Saúde. Secretaria de Atenção à Saúde; Protocolos Clínicos e Diretrizes Terapêuticas, v. 1; eds. Paulo Dornelles Picon, Maria Inez Pordeus Gadelha, Alberto Beltrame. Brasília: Ministério da Saúde; 2010. Brasil, Ministério da Saúde. Secretaria de Atenção à Saúde; Protocolos Clínicos e Diretrizes Terapêuticas, v. 1; eds. Paulo Dornelles Picon, Maria Inez Pordeus Gadelha, Alberto Beltrame. Brasília: Ministério da Saúde; 2010.
3.
go back to reference Tan D, Lao Z, Loh Y, Ng HJ, Chuah C, Wong GC, et al. Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma. Bone Marrow Transplant. 2010;45:1625–30.CrossRefPubMed Tan D, Lao Z, Loh Y, Ng HJ, Chuah C, Wong GC, et al. Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma. Bone Marrow Transplant. 2010;45:1625–30.CrossRefPubMed
4.
go back to reference Mateos MV, San Miguel JF. Old and new treatments in non-transplant candidate newly diagnosed multiple myeloma patients. In: Hematology Education: the education programme for the annual congress of the European Hematology Association. Amsterdam: EHA; 2012. p. 221–8. Mateos MV, San Miguel JF. Old and new treatments in non-transplant candidate newly diagnosed multiple myeloma patients. In: Hematology Education: the education programme for the annual congress of the European Hematology Association. Amsterdam: EHA; 2012. p. 221–8.
5.
go back to reference Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefPubMed Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefPubMed
6.
go back to reference Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMed Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMed
7.
go back to reference Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 2009;360:2645–54.CrossRefPubMed Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 2009;360:2645–54.CrossRefPubMed
8.
go back to reference Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.CrossRefPubMed Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23:3–9.CrossRefPubMed
10.
go back to reference Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010;16:1122–9.CrossRefPubMedPubMedCentral Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. Biol Blood Marrow Transplant. 2010;16:1122–9.CrossRefPubMedPubMedCentral
12.
go back to reference Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, et al. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002;116:211–7.CrossRefPubMed Tricot G, Spencer T, Sawyer J, Spoon D, Desikan R, Fassas A, et al. Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol. 2002;116:211–7.CrossRefPubMed
Metadata
Title
Efficacy of a referral center for patient-centered care in multiple myeloma: a cohort study
Authors
Indara C. Saccilotto
Rosane Isabel Bittencourt
Camila C. Fischer
Amanda Quevedo
Vania N. Hirakata
Paulo D. Picon
Publication date
01-06-2015
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2015
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-015-1123-6

Other articles of this Issue 1/2015

BMC Health Services Research 1/2015 Go to the issue